✨ Free AI Report
Neos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Neos Therapeutics, Inc.
Research Preview

Neos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...

Analyst-debate audio for Neos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Neos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Neos Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Niche ADHD pharma play with established products but constrained by micro-cap valuation and thin pipeline...

Read the full analyst-debate transcript →
Industry ADHD pharmaceutical treatments
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: July 27, 2026
AI-Verified Research
30+ Page Report

Get the Latest Neos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Neos Therapeutics, Inc. Overview

Pro stress-test →

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD treatment, plus generic Tussionex for cough and cold symptoms. As of May 24, 2026, the market cap is $57.23M.

Strategic Profile

Pro stress-test →

The company generated $62.5 million in annual revenue in 2026, positioning it as a specialized ADHD-focused pharmaceutical company. Neos is advancing clinical-stage pipeline with NT0502 for the treatment of sialorrhea in patients with neurological conditions, though its core business remains ADHD products and generic cough/cold formulations.

Competitive Landscape

Pro stress-test →

Top competitors include Cingulate, SciNeuro and STALICLA. Neos competes in the ADHD treatment space with branded and extended-release formulations, though its scale is significantly smaller than larger pharma players. The company also competes in generic cough/cold markets with Tussionex, a more commoditized segment.

Industry Context

Neos Therapeutics, Inc. operates in ADHD pharmaceutical treatments.

Key facts

Founded: 2008 · Headquarters: Grand Prairie, Texas, US · Employees: 15 · Revenue: $62.5M (2026) · Market cap: $57.23M (as of May 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Neos Therapeutics, Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Neos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cingulate Inc.ADHD treatment competitor→Adlon TherapeuticsADHD treatment developer→Aytu BioPharmaExtended-release ADHD medications including Cotempla XR-ODT competitor→NaurexCNS disorder and ADHD treatment developer→

Compare Neos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neos Therapeutics, Inc. operates in ADHD pharmaceutical treatments. See how the rest of the sector scores on the Cyborg framework.

Browse ADHD pharmaceutical treatments research →
NEW · MCP server

Ask your AI assistant about Neos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Neos Therapeutics, Inc. do this quarter?”
“Is Neos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Neos Therapeutics, Inc. do?+
Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...
What is Neos Therapeutics, Inc.'s Cyborg Score?+
Neos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neos Therapeutics, Inc.'s main competitors?+
Named competitors include Cingulate Inc., Adlon Therapeutics, Aytu BioPharma, Naurex. The full competitive landscape is in the AskCyborg report.
How can I get the full Neos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Phnom Penh Water Supply Authority9ESCO Technologies Inc.9Evolution Mining Limited9CoreWeave, Inc.9Nintendo Co., Ltd.9Waste Management, Inc.9CrowdStrike Holdings, Inc.9SK Hynix Inc.9Kweichow Moutai Co., Ltd.9Apple Inc.8Domino's Pizza, Inc.8Pro-Dex, Inc.8Palladyne AI Corp.8Mo-BRUK S.A.8Kuwait Reinsurance Company K.S.C.P.8Red River Bancshares, Inc.8PTC India Limited8IsoEnergy Ltd.